Patent eligibility for software and life science has been a controversial issue for decades. And it has not resolved itself despite a set of US Supreme Court's decisions seeking to clarify the patent eligibility standard. The USPTO has issued memos after each decision with guidelines that tend to befuddle applicants and examiners. So this 69 page report appears to restate the support (pages 23-27) and critical views (pages 27-33) rather than a solution. Sure Congress can amend the patent eligibility standard, but the money at stake will always drive the new standard into controversy.
Monday, July 31, 2017
USPTO - Patent Eligible Subject Matter: Report on Views and Recommendations from the Public
The USPTO's Report: Patent Eligible Subject Matter: Report on Views and Recommendations from the Public.
Patent eligibility for software and life science has been a controversial issue for decades. And it has not resolved itself despite a set of US Supreme Court's decisions seeking to clarify the patent eligibility standard. The USPTO has issued memos after each decision with guidelines that tend to befuddle applicants and examiners. So this 69 page report appears to restate the support (pages 23-27) and critical views (pages 27-33) rather than a solution. Sure Congress can amend the patent eligibility standard, but the money at stake will always drive the new standard into controversy.
Patent eligibility for software and life science has been a controversial issue for decades. And it has not resolved itself despite a set of US Supreme Court's decisions seeking to clarify the patent eligibility standard. The USPTO has issued memos after each decision with guidelines that tend to befuddle applicants and examiners. So this 69 page report appears to restate the support (pages 23-27) and critical views (pages 27-33) rather than a solution. Sure Congress can amend the patent eligibility standard, but the money at stake will always drive the new standard into controversy.
